Table 6Strengths and Limitations of Economic Studies using the Drummond Checklist7

StrengthsLimitations
Van Werkhoven, 201720
  • Multiple perspectives were utilized and were clearly stated
  • Well-defined research question
  • Appropriate alternatives were examined
  • Effectiveness established through RCT
  • Productivity losses were appropriately discounted
  • Authors commented on the generalizability of results
  • Missing data was a potential limitation that may have introduced uncertainty
  • Cost differences in favor of FQs may have been inflated by physician tendency to start with oral FQ
  • Unclear if capital costs included
  • Self-reported data was used

FQ = fluoroquinolone; RCT = randomized control trial;

From: Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Cover of Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines
Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
Cowling T, Farrah K.
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.